Marshall Wace’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $530M | Sell |
576,174
-632,162
| -52% | -$641M | 0.53% | 20 |
|
|
2025
Q4 | $1.3B | Buy |
1,208,336
+1,045,251
| +641% | +$999M | 1.18% | 7 |
|
|
2025
Q3 | $124M | Sell |
163,085
-768,648
| -82% | -$572M | 0.13% | 131 |
|
|
2025
Q2 | $726M | Buy |
931,733
+512,229
| +122% | +$398M | 0.82% | 12 |
|
|
2025
Q1 | $346M | Buy |
419,504
+30,820
| +8% | +$25.6M | 0.44% | 34 |
|
|
2024
Q4 | $300M | Sell |
388,684
-521,448
| -57% | -$432M | 0.36% | 37 |
|
|
2024
Q3 | $806M | Buy |
910,132
+120,571
| +15% | +$108M | 0.98% | 13 |
|
|
2024
Q2 | $715M | Buy |
789,561
+366,271
| +87% | +$293M | 0.95% | 8 |
|
|
2024
Q1 | $329M | Sell |
423,290
-297,256
| -41% | -$212M | 0.5% | 24 |
|
|
2023
Q4 | $420M | Buy |
720,546
+126,477
| +21% | +$73.8M | 0.71% | 18 |
|
|
2023
Q3 | $319M | Buy |
594,069
+497,640
| +516% | +$256M | 0.65% | 21 |
|
|
2023
Q2 | $45.2M | Sell |
96,429
-592,667
| -86% | -$249M | 0.09% | 238 |
|
|
2023
Q1 | $237M | Buy |
689,096
+553,096
| +407% | +$187M | 0.5% | 31 |
|
|
2022
Q4 | $49.8M | Sell |
136,000
-264,245
| -66% | -$93.7M | 0.11% | 202 |
|
|
2022
Q3 | $129M | Sell |
400,245
-733,148
| -65% | -$232M | 0.28% | 63 |
|
|
2022
Q2 | $367M | Buy |
+1,133,393
| New | +$340M | 0.76% | 9 |
|
|
2022
Q1 | – | Sell |
-2,137
| Closed | -$591K | – | 3709 |
|
|
2021
Q4 | $591K | Sell |
2,137
-151,748
| -99% | -$38.5M | ﹤0.01% | 2720 |
|
|
2021
Q3 | $35.6M | Buy |
153,885
+59,571
| +63% | +$14.7M | 0.15% | 132 |
|
|
2021
Q2 | $21.6M | Buy |
94,314
+74,151
| +368% | +$14.9M | 0.1% | 215 |
|
|
2021
Q1 | $3.77M | Sell |
20,163
-192,051
| -90% | -$37.6M | 0.02% | 997 |
|
|
2020
Q4 | $35.8M | Buy |
212,214
+27,204
| +15% | +$4.06M | 0.19% | 109 |
|
|
2020
Q3 | $27.4M | Buy |
185,010
+21,902
| +13% | +$3.39M | 0.18% | 126 |
|
|
2020
Q2 | $26.8M | Buy |
163,108
+163,099
| +1,812,211% | +$25M | 0.19% | 120 |
|
|
2020
Q1 | $1K | Buy |
9
+4
| +80% | +$550 | ﹤0.01% | 1583 |
|
|
2019
Q4 | $1K | Buy |
+5
| New | +$580 | ﹤0.01% | 1638 |
|
|
2018
Q3 | – | Sell |
-9,545
| Closed | -$814K | – | 1227 |
|
|
2018
Q2 | $814K | Buy |
+9,545
| New | +$784K | 0.01% | 531 |
|
|
2017
Q2 | – | Sell |
-147,492
| Closed | -$12.4M | – | 356 |
|
|
2017
Q1 | $12.4M | Buy |
147,492
+12,133
| +9% | +$972K | 0.6% | 47 |
|
|
2016
Q4 | $9.96M | Buy |
+135,359
| New | +$10.1M | 0.07% | 338 |
|
|
2016
Q3 | – | Sell |
-160,446
| Closed | -$12.6M | – | 1048 |
|
|
2016
Q2 | $12.6M | Buy |
160,446
+128,288
| +399% | +$9.66M | 0.11% | 209 |
|
|
2016
Q1 | $2.32M | Sell |
32,158
-35,449
| -52% | -$2.68M | 0.02% | 530 |
|
|
2015
Q4 | $5.7M | Sell |
67,607
-515,198
| -88% | -$42.8M | 0.05% | 349 |
|
|
2015
Q3 | $48.8M | Buy |
582,805
+5,039
| +0.9% | +$425K | 0.6% | 35 |
|
|
2015
Q2 | $48.2M | Buy |
+577,766
| New | +$44M | 0.63% | 33 |
|
|
2015
Q1 | – | Sell |
-245,452
| Closed | -$16.9M | – | 876 |
|
|
2014
Q4 | $16.9M | Buy |
245,452
+78,958
| +47% | +$5.33M | 0.22% | 121 |
|
|
2014
Q3 | $10.8M | Buy |
166,494
+161,722
| +3,389% | +$10.2M | 0.16% | 176 |
|
|
2014
Q2 | $297K | Sell |
4,772
-25,085
| -84% | -$1.5M | ﹤0.01% | 766 |
|
|
2014
Q1 | $1.76M | Buy |
+29,857
| New | +$1.67M | 0.03% | 379 |
|
Other funds holding LLY
VCM
VPM
Marshall Wace's LLY Position: Q1 2026 in Review
Marshall Wace reduced its Eli Lilly (LLY) stake by 52% in Q1 2026, selling an estimated $641M and leaving 576,174 shares worth $530M. The position accounts for 0.53% of the portfolio, ranked #20.
Marshall Wace first reported a position in LLY in Q1 2014 and has held it in 37 quarters since. The position peaked at $1.3B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Marshall Wace held 576,174 shares of Eli Lilly worth $530M as of Q1 2026.
- Marshall Wace sold 632,162 Eli Lilly shares in Q1 2026, an estimated $641M.
- Eli Lilly made up 0.53% of Marshall Wace's portfolio in Q1 2026, its #20 holding.
- Marshall Wace first reported a position in Eli Lilly in Q1 2014 and has held it in 37 quarters since.
- Marshall Wace's Eli Lilly position peaked at $1.3B in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.